Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07621718 · ClinicalTrials.gov registry record · Phase 3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
A Phase 3 study, sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 670
- Enrollment target
NCT07621718: Recruiting Phase 3 study, sponsored by Revolution Medicines.
NCT07621718 is a Phase 3 study that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 670 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07621718, a Phase 3 study, is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 670 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
Primary Outcome
PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is assessed per response evaluation criteria in solid tumors (RECIST) v1.1 by Investigator.
Interventions
- DRUG Placebo
- DRUG Oxaliplatin
- DRUG 5-Fluorouracil
- DRUG Zoldonrasib
- DRUG Leucovorin (Calcium Folinate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 670 participants |
| Start Date | 2026-05-22 |
| Est. Completion | 2030-04-22 |
| Phase | Phase 3 |
What NCT07621718 shows while recruiting
NCT07621718 is an interventional study that assigns participants to a tested intervention. The registered 670 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT07621718 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07621718 about?
NCT07621718 is a clinical study titled "Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )". The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
What is the current status of trial NCT07621718?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 670 participants. The study started on 2026-05-22. Estimated completion is 2030-04-22.
What interventions are being tested in trial NCT07621718?
The interventions under investigation include: Placebo (DRUG), Oxaliplatin (DRUG), 5-Fluorouracil (DRUG), Zoldonrasib (DRUG), Leucovorin (Calcium Folinate) (DRUG).
Who is sponsoring clinical trial NCT07621718?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07621718's enrollment target sits among peer trials
670 546th of 2000 higher than 1,454 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02984761 · 670 participants · NA
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- NCT05727904 · 670 participants · Phase 3
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- NCT06223867 · 670 participants · NA
Efficacy, Effectiveness, and Implementation of Jaspr Health in Emergency Department- Part A
- NCT07184944 · 671 participants · Phase 3
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI